BRPI0915887A2 - derivados de indol macrocíclicos úteis como inibidores do vírus da hepatite c - Google Patents

derivados de indol macrocíclicos úteis como inibidores do vírus da hepatite c

Info

Publication number
BRPI0915887A2
BRPI0915887A2 BRPI0915887A BRPI0915887A BRPI0915887A2 BR PI0915887 A2 BRPI0915887 A2 BR PI0915887A2 BR PI0915887 A BRPI0915887 A BR PI0915887A BR PI0915887 A BRPI0915887 A BR PI0915887A BR PI0915887 A2 BRPI0915887 A2 BR PI0915887A2
Authority
BR
Brazil
Prior art keywords
hepatitis
indole derivatives
derivatives useful
virus inhibitors
macrocyclic indole
Prior art date
Application number
BRPI0915887A
Other languages
English (en)
Inventor
Abdellah Tahri
Katie Ingrid Eduard Amssoms
Pierre Jean-Marie Bernard Raboisson
Sandrine Marie Hélène Vendeville
Tse-I Lin
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of BRPI0915887A2 publication Critical patent/BRPI0915887A2/pt
Publication of BRPI0915887B1 publication Critical patent/BRPI0915887B1/pt
Publication of BRPI0915887B8 publication Critical patent/BRPI0915887B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0915887A 2008-07-08 2009-07-08 derivados de indol macrocíclicos úteis como inibidores do vírus da hepatite c BRPI0915887B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP08159965.6 2008-07-08
EP08159965 2008-07-08
EP08160254 2008-07-11
EP08160254.2 2008-07-11
EP08161743.3 2008-08-04
EP08161743 2008-08-04
PCT/EP2009/004942 WO2010003658A1 (en) 2008-07-08 2009-07-08 Macrocyclic indole derivatives useful as hepatitis c virus inhibitors

Publications (3)

Publication Number Publication Date
BRPI0915887A2 true BRPI0915887A2 (pt) 2015-11-03
BRPI0915887B1 BRPI0915887B1 (pt) 2020-02-18
BRPI0915887B8 BRPI0915887B8 (pt) 2021-05-25

Family

ID=40972916

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915887A BRPI0915887B8 (pt) 2008-07-08 2009-07-08 derivados de indol macrocíclicos úteis como inibidores do vírus da hepatite c

Country Status (31)

Country Link
US (2) US8921355B2 (pt)
EP (1) EP2310396B1 (pt)
JP (2) JP5426671B2 (pt)
KR (1) KR101640374B1 (pt)
CN (1) CN102089314B (pt)
AP (1) AP2743A (pt)
AR (1) AR072726A1 (pt)
AU (1) AU2009267389B8 (pt)
BR (1) BRPI0915887B8 (pt)
CA (1) CA2729307C (pt)
CL (1) CL2011000032A1 (pt)
CO (1) CO6351793A2 (pt)
CR (1) CR20110076A (pt)
DK (1) DK2310396T3 (pt)
EA (1) EA019008B1 (pt)
EC (1) ECSP11010750A (pt)
ES (1) ES2651038T3 (pt)
HN (1) HN2011000072A (pt)
HR (1) HRP20171892T1 (pt)
HU (1) HUE035244T2 (pt)
IL (1) IL210086A (pt)
LT (1) LT2310396T (pt)
MX (1) MX2011000276A (pt)
NI (1) NI201100010A (pt)
NO (1) NO2310396T3 (pt)
NZ (2) NZ603343A (pt)
SI (1) SI2310396T1 (pt)
SV (1) SV2011003796A (pt)
TW (1) TWI454476B (pt)
UY (1) UY31973A (pt)
WO (1) WO2010003658A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524716B2 (en) 2007-12-24 2013-09-03 Janssen R&D Ireland Macrocyclic indoles as hepatitis C virus inhibitors
TWI454476B (zh) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
UA108211C2 (uk) * 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
NZ602552A (en) * 2010-04-13 2014-09-26 Janssen Pharmaceuticals Inc Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
WO2011161232A1 (en) 2010-06-24 2011-12-29 Tibotec Pharmaceuticals PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID
EP2760821B1 (en) 2011-09-02 2017-10-11 Novartis AG Choline salt of an anti-inflammatory substituted cyclobutenedione compound
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
KR20150046083A (ko) 2012-08-31 2015-04-29 얀센 파마슈티칼즈, 인코포레이티드 Ｈｃｖ의 거대환형 프로테아제 저해제, 비­뉴클레오시드계 ｈｃｖ 저해제 및 리토나비르의 조합물
WO2014152275A1 (en) * 2013-03-14 2014-09-25 Concert Pharmaceuticals, Inc. Deuterium modified derivatives of the ns5b polymerase inhibitor tmc647055
US10450263B2 (en) 2017-02-10 2019-10-22 Southern Research Institute Benzo annulenes as antiviral agents
KR101974388B1 (ko) 2017-06-23 2019-05-02 (주)에니켐텍 알킬 디에틸렌 트리아민 유도체 및 이의 제조방법
US11066357B2 (en) 2017-12-26 2021-07-20 Southern Research Institute Benzoannulene derivatives as antiviral agents
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
US12060148B2 (en) 2022-08-16 2024-08-13 Honeywell International Inc. Ground resonance detection and warning system and method
CN116425782A (zh) * 2023-03-22 2023-07-14 烟台盛凯伦化学科技有限公司 一种5-乙酰基-2-氟苯硼酸频哪醇酯的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US20050267836A1 (en) * 1996-03-25 2005-12-01 Cfph, Llc Method and system for transacting with a trading application
CZ298463B6 (cs) 1996-04-23 2007-10-10 Vertex Pharmaceuticals Incorporated Deriváty mocoviny pro použití jako inhibitory IMPDH enzymu a farmaceutické prostredky, které je obsahují
AU6701598A (en) 1997-03-14 1998-09-29 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
SK13332001A3 (sk) 1999-03-19 2002-02-05 Vertex Pharmaceuticals Incorporated Inhibítory IMPDH enzýmu a ich použitie
US6891331B2 (en) 2000-08-30 2005-05-10 Matsushita Electric Industrial Co., Ltd. Plasma display unit and production method thereof
KR20120090077A (ko) 2004-01-30 2012-08-16 얀센 알 앤드 디 아일랜드 Ｈｃｖ ｎｓ?３ 세린 프로테아제 저해제
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
RU2008112661A (ru) 2005-09-02 2009-10-10 Тиботек Фармасьютикалз Лтд. (Ie) Бензодиазепины в качестве ингибиторов hcv
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
GB0522881D0 (en) 2005-11-10 2005-12-21 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007092000A1 (en) 2006-02-06 2007-08-16 Bristol-Myers Squibb Company Inhibitors of hcv replication
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2007140200A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
MX2009003452A (es) 2006-10-10 2009-04-14 Medivir Ab Inhibidores nucleosidicos del vhc.
CA2672250C (en) * 2006-12-20 2013-04-30 Ian Stansfield Antiviral indoles
JP2010533699A (ja) * 2007-07-17 2010-10-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Ｃ型肝炎感染症の治療のための大環状インドール誘導体
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
TW201023858A (en) 2008-09-18 2010-07-01 Ortho Mcneil Janssen Pharm Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
MX340792B (es) 2009-02-27 2016-07-25 Ortho-Mcneil-Janssen Pharmaceuticals Inc * Sal amorfa de un inhibidor macrociclico de virus de hepatitis c.
NZ602552A (en) 2010-04-13 2014-09-26 Janssen Pharmaceuticals Inc Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
WO2011161232A1 (en) 2010-06-24 2011-12-29 Tibotec Pharmaceuticals PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID
KR20150046083A (ko) 2012-08-31 2015-04-29 얀센 파마슈티칼즈, 인코포레이티드 Ｈｃｖ의 거대환형 프로테아제 저해제, 비­뉴클레오시드계 ｈｃｖ 저해제 및 리토나비르의 조합물

Also Published As

Publication number Publication date
SI2310396T1 (en) 2018-01-31
CN102089314A (zh) 2011-06-08
CL2011000032A1 (es) 2011-07-15
LT2310396T (lt) 2017-12-27
AU2009267389B8 (en) 2013-07-04
CR20110076A (es) 2011-11-10
WO2010003658A1 (en) 2010-01-14
US9427440B2 (en) 2016-08-30
CA2729307A1 (en) 2010-01-14
TWI454476B (zh) 2014-10-01
AR072726A1 (es) 2010-09-15
NZ603343A (en) 2013-08-30
JP5426671B2 (ja) 2014-02-26
TW201014865A (en) 2010-04-16
JP2014028818A (ja) 2014-02-13
ECSP11010750A (es) 2011-08-31
SV2011003796A (es) 2011-04-08
HUE035244T2 (hu) 2018-05-02
IL210086A (en) 2014-05-28
JP5808370B2 (ja) 2015-11-10
IL210086A0 (en) 2011-02-28
KR101640374B1 (ko) 2016-07-18
CN102089314B (zh) 2014-07-23
DK2310396T3 (en) 2017-12-11
US20110105473A1 (en) 2011-05-05
NZ590073A (en) 2012-11-30
EA019008B1 (ru) 2013-12-30
BRPI0915887B8 (pt) 2021-05-25
UY31973A (es) 2010-01-29
AP2010005521A0 (en) 2010-12-31
NO2310396T3 (pt) 2018-02-03
ES2651038T3 (es) 2018-01-23
AU2009267389A1 (en) 2010-01-14
KR20110040889A (ko) 2011-04-20
HK1155734A1 (en) 2012-05-25
AU2009267389B2 (en) 2013-05-30
US8921355B2 (en) 2014-12-30
JP2011527299A (ja) 2011-10-27
CA2729307C (en) 2017-08-29
EP2310396B1 (en) 2017-09-06
EP2310396A1 (en) 2011-04-20
AU2009267389A8 (en) 2013-07-04
BRPI0915887B1 (pt) 2020-02-18
EA201170153A1 (ru) 2011-08-30
AP2743A (en) 2013-09-30
HRP20171892T1 (hr) 2018-01-12
HN2011000072A (es) 2013-09-01
NI201100010A (es) 2011-09-07
US20140107101A1 (en) 2014-04-17
CO6351793A2 (es) 2011-12-20
MX2011000276A (es) 2011-03-02

Similar Documents

Publication Publication Date Title
BRPI0821836A2 (pt) Indóis macrocíclicos como inibidores do vírus da hepatite c
IL210086A0 (en) Macrocyclic indole derivatives useful as hepatitis c virus inhibitors
BR112012002508A2 (pt) derivados de feniletinila como inibidores de vírus de hepatite c
BRPI0908240A2 (pt) inibidores do vírus da hepatite c
BRPI0907733A2 (pt) Inibidores do vírus da hepatite c
BRPI0906625A2 (pt) Derivados de tio-2-amino-quinolina-6-substituída úteis como inibidores da beta-secretase (bace)
BRPI0820085A2 (pt) compostos contendo quinoxalina como inibidores de vírus da hepatite c
BRPI0911444A2 (pt) benzoimidazóis como inibidores de prolil hidroxilase
BRPI1007836A2 (pt) Inibidores do vírus c da hepatite
BRPI1008846A2 (pt) inibidores do vírus da hepatite c
BRPI1013393A2 (pt) inibidores do vírus da hepatite c
PT2860179T (pt) Derivados de pirazolo-piridina como inibidores de nadph-oxidase
BRPI0922912A8 (pt) peptídeos de 4-amino-4-oxobutanoil como inibidores de replicação viral
EP2266989A4 (en) HETEROCYCLIC DERIVATIVES
BRPI0923497A2 (pt) derivados de piridazinona
BRPI0915064A2 (pt) derivados de qunoxalinadiona
BRPI0809221A2 (pt) indol carboxamidas como inibidores de ikk2
BRPI1008855A2 (pt) derivados de indol como agentes anticâncer
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0914942A2 (pt) Compostos de oxindol
IL207684A0 (en) Substituted indole derivatives
BRPI0912234A2 (pt) derivados de salinosporamida como inibidores de proteassomas
PT2513105E (pt) Derivados de 2-arilimidazole como inibidores da enzima pde10a
BR112013002122A2 (pt) derivados hetero-bicíclicos como inibidores de hcv
BRPI1012852A2 (pt) derivados de benzoxazolona como inibidores da sintase de aldoesterona

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF